IDEAYA Biosciences (NASDAQ:IDYA) Given New $52.00 Price Target at Guggenheim

Posted by George Bondi on Nov 4th, 2026

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) had its price target lowered by Guggenheim from $57.00 to $52.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim‘s price objective points to a potential upside of 65.25% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on IDYA. William Blair started coverage on shares of IDEAYA Biosciences in a report on Friday, October 16th. They issued an “outperform” rating for the company. Truist Financial set a $57.00 price target on shares of IDEAYA Biosciences in a research note on Tuesday. Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Citizens Jmp reissued a “market outperform” rating and set a $42.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 1st. Finally, Wedbush upped their price objective on IDEAYA Biosciences from $60.00 to $63.00 and gave the stock an “outperform” rating in a report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.18.

Read Our Latest Analysis on IDEAYA Biosciences

IDEAYA Biosciences Stock Performance

NASDAQ IDYA traded up $0.14 during trading hours on Wednesday, reaching $31.47. The company’s stock had a trading volume of 109,762 shares, compared to its average volume of 1,022,769. The stock has a market cap of $2.76 billion, a PE ratio of -16.26 and a beta of 0.08. IDEAYA Biosciences has a fifty-two week low of $26.81 and a fifty-two week high of $42.68. The company’s 50-day moving average is $36.91 and its two-hundred day moving average is $34.05.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04). The company had revenue of $10.24 million during the quarter, compared to analyst estimates of $7.58 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The business’s revenue was up 14.6% compared to the same quarter last year. During the same period last year, the firm earned $1.33 earnings per share. Equities analysts expect that IDEAYA Biosciences will post -4.52 earnings per share for the current fiscal year.

Insider Activity at IDEAYA Biosciences

In other news, CEO Yujiro Hata sold 26,338 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $37.41, for a total value of $985,304.58. Following the completion of the sale, the chief executive officer owned 690,695 shares of the company’s stock, valued at $25,838,899.95. This represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IDYA. BlackRock Inc. acquired a new stake in IDEAYA Biosciences in the second quarter valued at $331,452,000. Jupiter Topco LLC bought a new position in IDEAYA Biosciences during the 2nd quarter valued at $319,728,000. Janus Henderson Group PLC grew its holdings in IDEAYA Biosciences by 1.1% during the 1st quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after acquiring an additional 78,797 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in IDEAYA Biosciences by 42.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,333,478 shares of the company’s stock worth $44,418,000 after acquiring an additional 394,621 shares in the last quarter. Finally, Candriam S.C.A. grew its holdings in IDEAYA Biosciences by 1.7% during the 3rd quarter. Candriam S.C.A. now owns 1,110,424 shares of the company’s stock worth $42,818,000 after acquiring an additional 18,123 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Trending Headlines about IDEAYA Biosciences

Here are the key news stories impacting IDEAYA Biosciences this week:

Positive Sentiment: Wedbush raised its price target to $63 from $60 and reiterated an “outperform” rating, implying substantial upside from the cited $32.11 share price. Wedbush ratings
Positive Sentiment: IDEAYA reported Q3 revenue of $10.24 million, above the $7.58 million estimate and up 14.6% year over year. Its business update also highlighted completed NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma, encouraging IDE849 trial data, and $1.15 billion in cash and securities with runway into 2030. Q3 results and business update
Neutral Sentiment: The company announced it will participate in investor-relations events in November; the announcement itself did not include new financial or clinical results. Investor-relations events announcement
Negative Sentiment: Truist lowered its price target to $57, a less favorable analyst update even though the new target remains above the cited share price. Truist price-target change
Negative Sentiment: IDEAYA posted a Q3 loss of $1.22 per share, narrowly worse than the $1.18 consensus estimate cited in the supplied results. The company continues to report substantial operating losses, underscoring its reliance on pipeline progress and future commercialization. Q3 results and business update

About IDEAYA Biosciences

(Get Free Report)

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.